Inventiva S.A. (IVA.PA)
EUR 2.84
(0.71%)
EUR 2.84
(0.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -102.7 Million EUR | -89.12% |
| 2022 | -57.11 Million EUR | -9.59% |
| 2021 | -52.11 Million EUR | -75.36% |
| 2020 | -29.71 Million EUR | 1.96% |
| 2019 | -30.31 Million EUR | 8.84% |
| 2018 | -33.25 Million EUR | -58.98% |
| 2017 | -20.91 Million EUR | -60.66% |
| 2016 | -13.01 Million EUR | 16.06% |
| 2015 | -15.5 Million EUR | -15.17% |
| 2014 | -13.46 Million EUR | -8.02% |
| 2013 | -12.46 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -52.24 Million EUR | 0.0% |
| 2023 Q2 | -55 Million EUR | 0.0% |
| 2023 FY | -108 Million EUR | -89.12% |
| 2023 Q4 | -47.7 Million EUR | 0.0% |
| 2022 Q4 | -23.61 Million EUR | 0.0% |
| 2022 Q2 | -36.52 Million EUR | 0.0% |
| 2022 FY | -57.11 Million EUR | -9.59% |
| 2021 Q2 | -13.66 Million EUR | -37.44% |
| 2021 Q1 | -9.94 Million EUR | 36.74% |
| 2021 FY | -52.11 Million EUR | -75.36% |
| 2021 Q4 | -30.69 Million EUR | 0.0% |
| 2020 FY | -29.71 Million EUR | 1.96% |
| 2020 Q1 | -6.8 Million EUR | 41.37% |
| 2020 Q2 | -8.86 Million EUR | -30.2% |
| 2020 Q4 | -15.71 Million EUR | 0.0% |
| 2019 FY | -30.31 Million EUR | 8.84% |
| 2019 Q4 | -11.6 Million EUR | 0.0% |
| 2019 Q2 | -21.58 Million EUR | -185.69% |
| 2019 Q1 | -7.55 Million EUR | 55.12% |
| 2018 Q4 | -16.83 Million EUR | 0.0% |
| 2018 FY | -33.25 Million EUR | -58.98% |
| 2018 Q2 | -16.07 Million EUR | -92.71% |
| 2018 Q1 | -8.34 Million EUR | 30.5% |
| 2017 FY | -20.91 Million EUR | -60.66% |
| 2017 Q1 | -5.15 Million EUR | 12.44% |
| 2017 Q2 | -10.89 Million EUR | -111.19% |
| 2017 Q4 | -12 Million EUR | 0.0% |
| 2016 Q4 | -5.89 Million EUR | 0.0% |
| 2016 Q2 | -6.16 Million EUR | -96.57% |
| 2016 Q1 | -3.13 Million EUR | 54.35% |
| 2016 FY | -13.01 Million EUR | 16.06% |
| 2015 FY | -15.5 Million EUR | -15.17% |
| 2015 Q4 | -6.87 Million EUR | -83.09% |
| 2015 Q3 | -3.75 Million EUR | 53.08% |
| 2015 Q2 | -8 Million EUR | -113.14% |
| 2015 Q1 | -3.75 Million EUR | 0.0% |
| 2014 FY | -13.46 Million EUR | -8.02% |
| 2014 Q2 | -3.17 Million EUR | 0.0% |
| 2014 Q1 | -3.17 Million EUR | 0.0% |
| 2014 Q3 | -3.17 Million EUR | 0.0% |
| 2014 Q4 | -3.75 Million EUR | -18.07% |
| 2013 Q3 | -2.92 Million EUR | 0.0% |
| 2013 Q1 | -2.92 Million EUR | 0.0% |
| 2013 Q4 | -3.17 Million EUR | -8.55% |
| 2013 FY | -12.46 Million EUR | 0.0% |
| 2013 Q2 | -2.92 Million EUR | 0.0% |
| 2012 Q4 | -2.92 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -2910.229% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 19.366% |
| Adocia SA | -17.62 Million EUR | -482.845% |
| Aelis Farma SA | -6.46 Million EUR | -1489.677% |
| Biophytis S.A. | -14.33 Million EUR | -616.591% |
| Advicenne S.A. | -6.45 Million EUR | -1490.661% |
| genOway Société anonyme | 2.06 Million EUR | 5073.089% |
| IntegraGen SA | -183.77 Thousand EUR | -55789.971% |
| Medesis Pharma S.A. | -4.22 Million EUR | -2328.487% |
| Neovacs S.A. | -6.9 Million EUR | -1386.909% |
| NFL Biosciences SA | -4.43 Million EUR | -2218.268% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -13097.651% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -3173.85% |
| Sensorion SA | -22.31 Million EUR | -360.359% |
| Theranexus Société Anonyme | -7.64 Million EUR | -1243.712% |
| TME Pharma N.V. | -5.62 Million EUR | -1726.262% |
| Valbiotis SA | -7.16 Million EUR | -1334.483% |
| TheraVet SA | -2.17 Million EUR | -4622.016% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -406.255% |
| DBV Technologies S.A. | -85.24 Million EUR | -20.485% |
| Genfit S.A. | -26.58 Million EUR | -286.415% |
| GeNeuro SA | -14.35 Million EUR | -615.378% |
| Innate Pharma S.A. | -12.66 Million EUR | -710.711% |
| MaaT Pharma SA | -19.94 Million EUR | -415.013% |
| MedinCell S.A. | -20.97 Million EUR | -389.627% |
| Nanobiotix S.A. | -26.77 Million EUR | -283.543% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -346.833% |
| Poxel S.A. | -28.76 Million EUR | -257.075% |
| GenSight Biologics S.A. | -29.69 Million EUR | -245.868% |
| Transgene SA | -30.01 Million EUR | -242.226% |
| Valneva SE | -82.08 Million EUR | -25.122% |